Plasma Fractionation Market - Global Forecast to 2023

DUBLIN, Feb. 12, 2018 /PRNewswire/ --

The "Plasma Fractionation Market by Product (IVIG, Albumin, Factor VIII, von Willebrand Factor, PCC, Protease Inhibitor), Application (Immunology, Hematology, Critical Care, Rheumatology), End User - Global Forecast to 2023" report has been added to ResearchAndMarkets.com's offering.

http://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg

The global plasma fractionation market is projected to reach USD 29.50 Billion by 2023 from USD 21.23 Billion in 2018, at a CAGR of 6.8%

Market growth can be attributed to factors such as the growing use of immunoglobulins in various therapeutic areas, rising geriatric population across the globe, growing prevalence of respiratory diseases and AATD driving the uptake of alpha-1-antitrypsin, and increase in plasma collection. However, the high cost & limited reimbursement policies and emergence of recombinant alternatives can hinder the growth of this market.

Rising new indications for plasma products, rising adoption of SCIg, increasing installation of fractionators in plasma collection centers, and the high growth of the plasma products market in China are the major trends in this market.

Geographically, the global plasma fractionation market is segmented into North America, Europe, Asia Pacific, and Latin America and the Middle East and Africa. In 2017, North America accounted for the largest share of this market. North America's prominence in this market is mainly attributed to the increasing use of immunoglobulins in neurological diseases and increasing use of prophylaxis treatments for diagnosed patients. In addition, the rising number of registered hemophilic patients is also propelling the growth of this market.

However, the high cost of plasma products, availability of limited reimbursement, serious adverse effects associated with these products, and the emergence of recombinant products (which can be used as an alternative to plasma products) are restraining the growth of the plasma fractionation market. In addition, high infrastructural costs, fixed manufacturing costs, and strict government regulations for plasma products are further restricting the growth of this market.

CSL (Australia), Grifols (Spain), Shire (Ireland), and Octapharma (Switzerland) dominated the global plasma fractionation market. Some of the other players competing in this market are LFB (France), Kedrion (Italy), Biotest (Germany), Sanquin (Netherlands), China Biologic Product, Bio Product Laboratory (UK), Japan Blood Products Organization, Green Cross Corporation (South Korea), Shanghai RAAS Blood Products (China), Beijing Tiantan Biological Products (China), and Bharat Serums and Vaccines (India).

Key Topics Covered:

1 Introduction

2 Research Methodology

3 Executive Summary

4 Premium Insights

5 Market Overview

6 Industry Insights

7 Plasma Fractionation Market, By Product

8 Plasma Fractionation Market, By Application

9 Plasma Fractionation Market, By End User

10 Geographic Analysis

11 Competitive Landscape

12 Company Profiles

    --  Beijing Tiantan Biological Products
    --  Bio Product Laboratory (BPL)
    --  Biotest
    --  CSL
    --  China Biologic Product
    --  Green Cross Corporation
    --  Grifols
    --  Japan Blood Products Organization
    --  Kedrion
    --  LFB
    --  Octapharma
    --  Sanquin
    --  Shanghai RAAS Blood Products
    --  Shire

For more information about this report visit https://www.researchandmarkets.com/research/bm5q7k/plasma?w=5

Media Contact:

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

View original content:http://www.prnewswire.com/news-releases/plasma-fractionation-market---global-forecast-to-2023-300596977.html

SOURCE Research and Markets